Company news

Imunon, Inc. news in 2025

Imunon, Inc.'s news releases, calls and decks from 2025, newest first.

View company

IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules

December 30, 2025

IMUNON 2025, a transformative year of significant clinical advances, looking ahead to 2026

December 29, 2025

IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update

November 13, 2025

IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer

November 10, 2025

IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer

November 10, 2025

IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment

November 7, 2025

IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025

November 6, 2025

IMUNON Announces Webcast of In-Person R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer

November 4, 2025

IMUNON to Present Phase 3 OVATION 3 Study of IMNN-001 in Advanced Ovarian Cancer at IGCS 2025 Annual Global Meeting

October 30, 2025

IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting

October 23, 2025

IMUNON Hosts R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer

October 19, 2025

IMUNON Invited to Present PlaCCine® DNA Technology Proof-of-Concept Data in Platform Presentations at Leading Vaccine Conferences

October 17, 2025

IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress

October 14, 2025

IMNN: OVATION 2 Translational Data Shows IMNN-001 Alters Tumor Microenvironment…

September 23, 2025

IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift

September 22, 2025

IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research

September 19, 2025

IMUNON to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

September 2, 2025

IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

August 28, 2025

IMNN: First Patient Dosed in Phase 3 OVATION 3 Trial…

August 7, 2025

IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call

August 5, 2025

IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update

August 5, 2025

IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

July 30, 2025

IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025

July 29, 2025

IMUNON Announces Stock Dividend Boosting Shareholder Value

July 28, 2025

IMUNON Announces Reverse Stock Split

July 23, 2025

IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan

July 15, 2025

IMUNON Submits Plan in Consultation with the Exchange to Ensure Compliance with Nasdaq’s Listing Requirement, Anticipates Additional Compliance Period

June 30, 2025

IMNN: Translational Data from OVATION 2 Presented…

June 20, 2025

IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025

June 18, 2025

IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™

June 17, 2025

Life Sciences Investor Forum: Now Available for Online Viewing

June 13, 2025

IMUNON to Present at the Zacks SCR Life Sciences Virtual Investor Forum on June 12th

June 5, 2025

IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study

June 3, 2025

IMUNON CEO recaps a year of clinical achievement and solid fundamentals

June 2, 2025

IMUNON Closes Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules

May 28, 2025

IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025

May 27, 2025

IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules

May 23, 2025

IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer

May 23, 2025

IMUNON Announces Withdrawal of Form S-1 Registration Statement

May 22, 2025

IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19

May 15, 2025

IMNN: First Site Activated for Phase 3 OVATION 3 Trial…

May 14, 2025

IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025

IMUNON Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

May 8, 2025

IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology

May 6, 2025

IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025

May 5, 2025

IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting

April 21, 2025

IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

March 24, 2025

IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study

February 27, 2025

IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19

February 26, 2025

IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025

February 20, 2025

Older news releases →

Calls in 2025

Decks in 2025